Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have provided informed consent prior to any study specific procedures.~* Participants currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder as confirmed by the Structured Clinical Interview (SCID) with a current with a current major depressive episode of at least 4 weeks and not exceeding 12 months in duration.~* Participants with normal physical examination, laboratory, vital signs, and/or echocardiogram (ECG).~* Verified previous manic or mixed episode.~* Participants with a total Hamilton Rating Scale for Depression (HAMD)-17 score ≥ 20.~* Participants with a HAMD-17 item 1 score ≥ 2.~* Participants with a Clinical Global Impression of Severity (CGI-S) score ≥ 4.~Exclusion Criteria:~* Participants with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I disorder that was the primary focus of treatment within the previous 6 months.~* Women who are pregnant or breast feeding~* Participants with Young Mania Rating Scale (YMRS) total score \> 10~* Participants who have dementia, mental retardation, schizophrenia/schizoaffective disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo orally once a day for 8 weeks.
- Cariprazine 0.75 mg (Type: EXPERIMENTAL): Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.
- Cariprazine 1.5 mg (Type: EXPERIMENTAL): Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.
- Cariprazine 3.0 mg (Type: EXPERIMENTAL): Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).